Online inquiry

IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2232MR)

This product GTTS-WQ2232MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets VWF gene. The antibody can be applied in Acute coronary syndrome (ACS), Thrombotic thrombocytopenia purpura (TTP) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000552.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7450
UniProt ID P04275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2232MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3293MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ9579MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ8043MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ12620MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ9922MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ6991MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ETI-204
GTTS-WQ2827MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-403
GTTS-WQ6162MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CP-751871
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW